Eli Lilly and Company (NYSE:LLY) Stock Falls 1.9% - What's Next?

Key Points

• Eli Lilly shares fell 1.9% amid broader healthcare-sector weakness, despite positive clinical-trial developments and stronger-than-expected quarterly results. The stock trades near $1,162, while analysts maintain a “Moderate Buy” consensus with a $1,311.96 average price target.
• Lilly reported encouraging obesity-drug results: the experimental EloraTZP combination produced up to 23.3% average weight loss, while retatrutide delivered nearly 21% weight loss in adults with diabetes and obesity. Phase 3 testing for EloraTZP is planned for late 2026.
• Competitive and reputational risks remain, including Novo Nordisk’s claim that higher-dose Ozempic showed lower cardiovascular-event risk than Mounjaro in a real-world study and criticism from Australian doctors over Lilly’s direct-to-home Mounjaro delivery model.

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) were down 1.9% on Wednesday. The company traded as low as $1,155.27 and last traded at $1,161.7290. Approximately 3,386,206 shares changed hands during trading, an increase of 13% from the average session volume of 2,996,803 shares. The stock had previously closed at $1,184.63.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported that its experimental EloraTZP combination of eloralintide and tirzepatide produced average weight loss of up to 23.3% in a Phase 2b trial, versus 14.8% for Zepbound 15 mg alone. The combination also delivered greater A1C reductions, and Lilly plans to begin Phase 3 testing in the fourth quarter of 2026. Lilly EloraTZP trial results
• Positive Sentiment: Late-stage data for retatrutide showed adults with type 2 diabetes and obesity lost nearly 21% of body weight, or about 50 pounds at the highest dose, while also improving blood sugar. The results strengthen Lilly’s long-term opportunity in obesity treatment, although the drug remains investigational. Retatrutide diabetes trial
• Positive Sentiment: Lilly’s Ebglyss met its primary and secondary endpoints in a Phase 3b trial for moderate-to-severe hand and foot atopic dermatitis, with more than half of patients achieving clear or almost clear skin by Week 16. This supports growth beyond the company’s diabetes and obesity franchise. Ebglyss dermatitis trial
• Neutral Sentiment: The broader healthcare sector was softer, creating a macro headwind for LLY despite its company-specific trial wins. Speculation that Lilly could eventually split its high-priced shares is not an earnings or valuation catalyst by itself. Healthcare sector update
• Negative Sentiment: Novo Nordisk said a real-world study found that patients escalating Ozempic to 2 mg had a lower observed risk of major cardiovascular events than patients who switched to Lilly’s Mounjaro. Although not a randomized head-to-head trial, the claim challenges Lilly’s competitive position in diabetes care. Novo cardiovascular study
• Negative Sentiment: Australian doctors criticized Lilly’s move to deliver Mounjaro directly to patients’ homes, arguing that bypassing in-person medical oversight could raise safety and prescribing concerns. The controversy may create regulatory and reputational risk as Lilly expands access. Mounjaro delivery criticism

Analyst Ratings Changes

LLY has been the subject of several analyst reports. Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 23rd. UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a report on Friday, August 7th. Citigroup upped their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th. Finally, HSBC raised their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a research report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,311.96.

Eli Lilly and Company Trading Down 1.9%

The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a market capitalization of $1.09 trillion, a PE ratio of 38.98, a PEG ratio of 1.46 and a beta of 0.50. The stock has a fifty day moving average of $1,178.09 and a 200 day moving average of $1,085.91.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter last year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 36.62 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Donald Zakrowski sold 2,000 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 over the last 90 days. Corporate insiders own 0.14% of the company's stock.

Institutional Trading of Eli Lilly and Company

Several hedge funds have recently modified their holdings of LLY. BlackRock Inc. lifted its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. State Street Corp raised its position in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after buying an additional 605,752 shares in the last quarter. Capital World Investors raised its position in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock valued at $16,154,619,000 after buying an additional 61,851 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $13,522,666,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after acquiring an additional 137,364 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.